Nektar Therapeutics/$NKTR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.

Ticker

$NKTR
Sector
Primary listing

Employees

61

NKTR Metrics

BasicAdvanced
$1.1B
-
-$8.72
1.07
-

Bulls say / Bears say

Rezpegaldesleukin’s Phase 2b REZOLVE-AD trial achieved both its primary and key secondary endpoints in moderate-to-severe atopic dermatitis, delivering rapid, statistically significant EASI improvements and itch relief at 16 weeks (Investopedia )
The FDA granted Fast Track designation to rezpegaldesleukin for severe-to-very severe alopecia areata, allowing more frequent regulatory interaction and possible rolling review to speed development (RTTNews )
Nektar fully enrolled 84 patients in its REZOLVE-AA Phase 2b study for severe alopecia areata, reducing risk for a key pipeline program and showing strong execution (Investing.com )
GAAP revenue dropped 52% year-over-year to $11.2 million in Q2 2025 after the sale of the Huntsville manufacturing facility, exposing Nektar’s ongoing lack of commercial product income (PRNewswire )
Cash and marketable securities declined from $269.1 million at December 31, 2024 to $175.9 million at June 30, 2025 despite a mid-year equity raise, highlighting significant cash burn even after fundraising (PRNewswire )
R&D expense remained high at $29.9 million in Q2 2025, almost unchanged from $29.7 million in Q2 2024, indicating ongoing heavy development spending with no product approvals to offset costs (PRNewswire )
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NKTR

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs
Buy Nektar Therapeutics stock | $NKTR Share Price | Lightyear